[go: up one dir, main page]

FR3048361B1 - Compositions pour le traitement des candidoses - Google Patents

Compositions pour le traitement des candidoses Download PDF

Info

Publication number
FR3048361B1
FR3048361B1 FR1651717A FR1651717A FR3048361B1 FR 3048361 B1 FR3048361 B1 FR 3048361B1 FR 1651717 A FR1651717 A FR 1651717A FR 1651717 A FR1651717 A FR 1651717A FR 3048361 B1 FR3048361 B1 FR 3048361B1
Authority
FR
France
Prior art keywords
treatment
candidoses
compositions
candidiasis
lactobacilli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1651717A
Other languages
English (en)
French (fr)
Other versions
FR3048361A1 (fr
Inventor
Adrien Nivoliez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexbiome Therapeutics SAS
Original Assignee
Biose
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1651717A priority Critical patent/FR3048361B1/fr
Application filed by Biose filed Critical Biose
Priority to CA3012557A priority patent/CA3012557A1/fr
Priority to BR112018067416-8A priority patent/BR112018067416B1/pt
Priority to PCT/EP2017/054701 priority patent/WO2017148975A1/fr
Priority to US16/077,114 priority patent/US11197899B2/en
Priority to ES17707061T priority patent/ES2951677T3/es
Priority to CN201780014361.3A priority patent/CN109069557A/zh
Priority to PL17707061.2T priority patent/PL3423072T3/pl
Priority to HUE17707061A priority patent/HUE062933T2/hu
Priority to EP17707061.2A priority patent/EP3423072B1/fr
Priority to RU2018132814A priority patent/RU2732244C2/ru
Publication of FR3048361A1 publication Critical patent/FR3048361A1/fr
Application granted granted Critical
Publication of FR3048361B1 publication Critical patent/FR3048361B1/fr
Priority to US17/523,352 priority patent/US20220125863A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1651717A 2016-03-01 2016-03-01 Compositions pour le traitement des candidoses Active FR3048361B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR1651717A FR3048361B1 (fr) 2016-03-01 2016-03-01 Compositions pour le traitement des candidoses
HUE17707061A HUE062933T2 (hu) 2016-03-01 2017-03-01 Candidiasis kezelésére szolgáló készítmények
PCT/EP2017/054701 WO2017148975A1 (fr) 2016-03-01 2017-03-01 Compositions pour le traitement des candidoses
US16/077,114 US11197899B2 (en) 2016-03-01 2017-03-01 Compositions for treating candidiasis infections
ES17707061T ES2951677T3 (es) 2016-03-01 2017-03-01 Composiciones para el tratamiento de la candidiasis
CN201780014361.3A CN109069557A (zh) 2016-03-01 2017-03-01 用于治疗念珠菌感染的组合物
CA3012557A CA3012557A1 (fr) 2016-03-01 2017-03-01 Compositions pour le traitement des candidoses
BR112018067416-8A BR112018067416B1 (pt) 2016-03-01 2017-03-01 Uso e combinação farmacêutica de lactobacilos e tiossulfato para o tratamento de candidíase
EP17707061.2A EP3423072B1 (fr) 2016-03-01 2017-03-01 Compositions pour le traitement des candidoses
RU2018132814A RU2732244C2 (ru) 2016-03-01 2017-03-01 Композиции для лечения кандидозных инфекций
PL17707061.2T PL3423072T3 (pl) 2016-03-01 2017-03-01 Kompozycje do leczenia kandydozy
US17/523,352 US20220125863A1 (en) 2016-03-01 2021-11-10 Compositions for treating candidiasis infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1651717A FR3048361B1 (fr) 2016-03-01 2016-03-01 Compositions pour le traitement des candidoses

Publications (2)

Publication Number Publication Date
FR3048361A1 FR3048361A1 (fr) 2017-09-08
FR3048361B1 true FR3048361B1 (fr) 2020-12-18

Family

ID=56411709

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1651717A Active FR3048361B1 (fr) 2016-03-01 2016-03-01 Compositions pour le traitement des candidoses

Country Status (10)

Country Link
US (2) US11197899B2 (ru)
EP (1) EP3423072B1 (ru)
CN (1) CN109069557A (ru)
CA (1) CA3012557A1 (ru)
ES (1) ES2951677T3 (ru)
FR (1) FR3048361B1 (ru)
HU (1) HUE062933T2 (ru)
PL (1) PL3423072T3 (ru)
RU (1) RU2732244C2 (ru)
WO (1) WO2017148975A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937324B (zh) * 2018-01-10 2020-01-21 中国科学院微生物研究所 一株卷曲乳杆菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK242083D0 (da) 1983-05-27 1983-05-27 Hansens Chr Bio Syst Vaginalkapsler
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
DK0956858T3 (da) * 1998-04-30 2002-01-28 Vesely Renata Maria Cavaliere Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
JP2003522731A (ja) 1998-12-11 2003-07-29 ウレックス バイオテック インク． 泌尿生殖器感染に対する処置および防止のための乳酸菌の経口投与方法
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
WO2006045347A1 (en) 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
US8329447B2 (en) * 2008-12-12 2012-12-11 Osel, Inc. Strain of Lactobacillus crispatus
ITRM20110477A1 (it) * 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
FR2992973B1 (fr) * 2012-07-09 2015-12-18 S P M D Nouvelle souche de lactobacillus crispatus
FR3018193B1 (fr) * 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
EP3164145A4 (en) * 2014-07-01 2018-01-17 Probi Usa, Inc. Bi-layer dual release probiotic tablets

Also Published As

Publication number Publication date
RU2732244C2 (ru) 2020-09-14
CA3012557A1 (fr) 2017-09-08
EP3423072C0 (fr) 2023-06-07
CN109069557A (zh) 2018-12-21
PL3423072T3 (pl) 2023-10-02
EP3423072A1 (fr) 2019-01-09
WO2017148975A1 (fr) 2017-09-08
ES2951677T3 (es) 2023-10-24
US20220125863A1 (en) 2022-04-28
FR3048361A1 (fr) 2017-09-08
BR112018067416A2 (pt) 2018-12-26
US11197899B2 (en) 2021-12-14
EP3423072B1 (fr) 2023-06-07
HUE062933T2 (hu) 2023-12-28
RU2018132814A (ru) 2020-04-01
RU2018132814A3 (ru) 2020-04-09
BR112018067416A8 (pt) 2022-08-30
US20190046593A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
EP3646877A4 (en) USE OF A COMPOSITION WITH EXOSOMES FROM STEM CELLS AS AN ACTIVE INGREDIENT TO PREVENT OR RELIEVE ITCHING
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
MA41013A (fr) Compositions comprenant des souches bactériennes
CO2018011933A2 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
EP3639832A4 (en) USE OF A COMPOSITION WITH EXOSOME FROM ADAPTIVE TISSUE STEM CELLS AS AN ACTIVE INGREDIENT TO RELIEVE DERMATITIS
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41060A (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
ES2917634T3 (es) Derivados de urea cíclica fusionados como antagonista de CRHR2
MA46548A (fr) Fsh pour le traitement de l'infertilité
EP3485892A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF LIGHTLY COGNITIVE INTERFERENCE OR DEMENTIA WITH HYDROGEN AS AN ACTIVE SUBSTANCE
MX2019001864A (es) Composicion antimicrobiana.
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EP3388446A4 (en) IMPROVED ANGIOGENESIS-INHIBITING PEPTIDE AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF ANGIOGENIC DISEASES THEREOF AS AN ACTIVE SUBSTANCE
FR3048361B1 (fr) Compositions pour le traitement des candidoses
MX2020012609A (es) Inhibidor del hif-1?, metodo de preparacion del mismo, y composicion farmaceutica para prevenir o tratar la enfermedad ocular asociada a la angiogenesis, que contiene el mismo como ingrediente activo.
FR3088542B1 (fr) Composition cicatrisante comprenant une eau électrolysée
FR3070263B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite
MA39272A (fr) Formulations à libération prolongée de gabapentine
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170908

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

TP Transmission of property

Owner name: NEXBIOME THERAPEUTICS, FR

Effective date: 20210413

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10